01
The Unicorn Signature
Pre-hypergrowth patterns
Tests whether company and workforce structure can concentrate future hypergrowth cases before the growth curve becomes obvious.
Research Portfolio 2026
Five studies. One panel.
Five applications of the same longitudinal workforce instrument examining different stages of company and organisational development.
02
The Defensible Shelf
Structural business vulnerability
Examines historical workforce structure and business-model exposure before later survival or failure outcomes.
03
The Closed Circuit
Capability and talent-network lock-in
Examines whether stated organisational transformation is visible in workforce capability and personnel exchange patterns.
04
The 1998 Head Start
Long-term organisational readiness
Tests whether structural characteristics visible decades earlier persist through later organisational development.
05
The Portable Asset
Capability decay before failure
Examines technical workforce composition before later organisational contraction in a defined AI-company cohort.
Research principles
Publication discipline
- Classification rules are fixed before outcome review where applicable.
- Historical and current layers remain separate.
- Failed and null signals are retained.
- Scope and measurement limitations are stated alongside findings.
Client Portfolio 2026
Twenty engagements. Twenty economic decisions.
Between February and August 2026, the Vivameda instrument was applied across acquisition, diligence, allocation, advisory, intermediation, operating growth and market-development questions.
Acquisition, diligence and allocation
- portfolio assessment
- target assessment
- acquisition diligence
- capital allocation
- financing signals
Advisory and intermediation
- client matching
- organisational assessment
- account intelligence
- exit-planning intelligence
- commercial targeting
Operating growth and market development
- market prioritisation
- buyer timing
- named-account selection
- commercial signals
- sector intelligence
What repeats across the work
Evidence standards across research and commercial application
01
Longitudinal comparison reveals information that present-day snapshots cannot.
02
A signal becomes meaningful only when its relevant universe and denominator are defined.
03
Peer-relative evidence can remain useful where absolute observation is incomplete.
04
Negative findings and discarded signals are part of the method.
05
Historical and current evidence may be shown together but are never blended into one artificial series.
From research to a defined universe
Apply the instrument to a defined population
The same constructions can be applied to a company list, market definition, investment portfolio, acquisition universe or commercial target population.
A typical engagement begins with one defined economic question and a defined universe. Vivameda then returns either a labelled feature file, a scored population or a written intelligence analysis.
Discuss a universePublication standard
The Research Portfolio and Client Portfolio are first-party Vivameda publications. The Research Portfolio documents Vivameda's methods, findings and limitations. The Client Portfolio documents commercial field applications under confidentiality arrangements. Neither should be represented as independent third-party validation unless separately supported by an external source.
SYSTEM REF · VMD.21921.120826.224